144 related articles for article (PubMed ID: 27019158)
21. Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects.
Huang F; Marzin K; Koenen R; Kammerer KP; Strelkowa N; Elgadi M; Haertter S
Pharmazie; 2021 May; 76(5):189-194. PubMed ID: 33964991
[TBL] [Abstract][Full Text] [Related]
22. Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.
Duan J; Yong CL; Garneau M; Amad M; Bolger G; De Marte J; Montpetit H; Otis F; Jutras M; Rhéaume M; White PW; Llinàs-Brunet M; Bethell RC; Cordingley MG
Xenobiotica; 2012 Feb; 42(2):164-72. PubMed ID: 21988548
[TBL] [Abstract][Full Text] [Related]
23. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.
Isakov V; Koloda D; Tikhonova N; Kikalishvili T; Krasavina E; Lekishvili K; Malaya I; Ryska M; Samsonov M; Tolkacheva V
Antimicrob Agents Chemother; 2016 Dec; 60(12):7098-7104. PubMed ID: 27645244
[TBL] [Abstract][Full Text] [Related]
25. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
Zomorodi K; Kankam M; Lu Y
Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342
[TBL] [Abstract][Full Text] [Related]
26. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
Cheng Y; Liu L; Xue Y; Zhou S; Li Y
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
[TBL] [Abstract][Full Text] [Related]
27. Effect of Food on the Bioavailability of Omadacycline in Healthy Participants.
Tzanis E; Manley A; Villano S; Tanaka SK; Bai S; Loh E
J Clin Pharmacol; 2017 Mar; 57(3):321-327. PubMed ID: 27539539
[TBL] [Abstract][Full Text] [Related]
28. Effect of a high-fat meal on the relative bioavailability of H3B-6527, a novel FGFR4 inhibitor, in healthy volunteers.
Rioux N; Kim A; Nix D; Bowser T; Warmuth M; Smith PG; Schindler J
Cancer Chemother Pharmacol; 2019 Jan; 83(1):91-96. PubMed ID: 30368584
[TBL] [Abstract][Full Text] [Related]
29. Relative bioavailability and pharmacokinetic study of omeprazole 20 mg enteric-coated tablet in healthy Bangladeshi volunteers.
Hasan A; Abul Kalam Azad M; Ullah MA; Mahbub Latif AH; Hasnat A
Int J Clin Pharmacol Ther; 2009 Mar; 47(3):215-21. PubMed ID: 19281731
[TBL] [Abstract][Full Text] [Related]
30. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
31. Impact of food and the proton pump inhibitor rabeprazole on the pharmacokinetics of GDC-0941 in healthy volunteers: bench to bedside investigation of pH-dependent solubility.
Ware JA; Dalziel G; Jin JY; Pellett JD; Smelick GS; West DA; Salphati L; Ding X; Sutton R; Fridyland J; Dresser MJ; Morrisson G; Holden SN
Mol Pharm; 2013 Nov; 10(11):4074-81. PubMed ID: 24099279
[TBL] [Abstract][Full Text] [Related]
32. Faldaprevir (BI 201335) for the treatment of hepatitis C in patients co-infected with HIV.
Laufer NL; Rockstroh JK
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):157-64. PubMed ID: 24350778
[TBL] [Abstract][Full Text] [Related]
33. Drug-drug interactions between sucroferric oxyhydroxide and losartan, furosemide, omeprazole, digoxin and warfarin in healthy subjects.
Chong E; Kalia V; Willsie S; Winkle P
J Nephrol; 2014 Dec; 27(6):659-66. PubMed ID: 24699894
[TBL] [Abstract][Full Text] [Related]
34. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
[TBL] [Abstract][Full Text] [Related]
35. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole.
de Kanter CT; Colbers AP; Blonk MI; Verweij-van Wissen CP; Schouwenberg BJ; Drenth JP; Burger DM
J Antimicrob Chemother; 2013 Jun; 68(6):1415-22. PubMed ID: 23429642
[TBL] [Abstract][Full Text] [Related]
36. Faldaprevir for the treatment of hepatitis C.
Campagna D; Demma S
Drugs Today (Barc); 2015 May; 51(5):289-301. PubMed ID: 26097902
[TBL] [Abstract][Full Text] [Related]
37. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
Shen J; Serby M; Reed A; Lee AJ; Zhang X; Marsh K; Khatri A; Menon R; Kavetskaia O; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1164-73. PubMed ID: 27179127
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study.
Shaik N; Hee B; Wei H; LaBadie RR
Cancer Chemother Pharmacol; 2019 Mar; 83(3):463-472. PubMed ID: 30536154
[TBL] [Abstract][Full Text] [Related]
40. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
